
Life Hack: How to treat sunburn and help it heal as fast as possible
Part of my day job involves monitoring trends on social media and search engines. Last week, I noticed a spike on Google Trends with people searching for ways to treat sunburn as quickly as possible.
Despite all the weather warnings and knowing we should stay in the shade and wear a high-factor SPF to protect our skin from cancer and accelerated signs of ageing, it's likely many readers of this column will also have slipped up in the sunshine and are now sporting some painful patches.
There's no judgement here: in the minutes between a dip in the ocean and reapplying suncream, my shoulders got burned too last week. Sometimes we just aren't quick enough to prevent it.
So, if you were unlucky and have the red stripes to prove it, here are some tried-and-tested ways to treat your sunburn and have your skin looking and feeling healthy as quickly as possible.
First steps
As soon as you realise you're burning, get out of the sun. Drink plenty of water to ensure you don't become dehydrated (and remember, beer and alcohol will not hydrate you).
To cool down your skin, don't use ice or an ice pack. Instead either hold a damp towel against your burn or have a cool shower or bath.
Slather on an aftersun cream, such as aloe vera. Do not use petroleum jelly on sunburn as this can actually trap heat into the skin, making it worse.
Keep your burned skin covered until it fully heals to protect it from direct sunlight and if you have any pain, you can take a painkiller such as paracetamol or ibuprofen. Never pop any blisters that may form and do not scratch or try to remove peeling skin.
Remember, severe sunburn is very serious and could lead to heat exhaustion or heat stroke. Contact your GP if your temperature is high, if you feel dizzy or sick, or if you have a headache and muscle cramps.
How long until it heals fully?
As well as feeling painful and uncomfortable, you can feel quite self-conscious after suffering sunburn.
Sunburned skin usually gets better after a week, but you can help it heal as fast as possible with a few extra steps, with most being quite intuitive.
As mentioned above, moisturising sunburn immediately can help to soothe it, but continuing to moisturise the area liberally can also help it to heal and fade faster. The best moisturisers for sunburn and irritated skin are the simple, unscented ones.
Many skincare brands make aqueous cream, a gentle emollient moisturiser that you can buy in a pharmacy for about €5. As well as hydrating the skin as a moisturiser, it can also be used as a cleanser.
Another cream I swear by for sunburn is La Roche Posay's Cicaplast Baume B5+, a repairing and soothing balm that helps to repair the skin barrier. I have used this on sunburn in the past and found it cleared up faster than usual.
You can also mix aloe vera into your usual lotion for a moisturising boost for dry and sun-damaged skin.
Hydration from the inside out is also key to healing. Continue to drink plenty of water while your skin recovers, around eight glasses a day. When we are properly hydrated, the body's healing process quickens, shortening recovery time. It can also help to regulate a higher body temperature caused by sunburn.
Another important consideration is knowing when to leave your sunburn alone. Ignore the itch and the urge to peel any flaking skin away — the skin underneath is healing and needs that layer to stay in place for now.
Constantly scratching at your sunburn will slow down your body's healing and can also increase the risk of an infection, setting you back even further on the recovery timeline.
Read More
Life Hack: Two TikTok cleaning techniques I use when tidying my home

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Should You Invest in Penumbra (PEN)?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Penumbra, Inc. (NYSE:PEN). Headquartered in Alameda, California, Penumbra, Inc. (NYSE:PEN) designs and manufactures medical devices. The one-month return of Penumbra, Inc. (NYSE:PEN) was 1.25%, and its shares gained 48.44% of their value over the last 52 weeks. On July 30, 2025, Penumbra, Inc. (NYSE:PEN) stock closed at $254.21 per share, with a market capitalization of $9.914 billion. Baron Health Care Fund stated the following regarding Penumbra, Inc. (NYSE:PEN) in its second quarter 2025 investor letter: "We added to our position in Penumbra, Inc. (NYSE:PEN), a medical device company that manufactures mechanical thrombectomy devices to remove clots. We think Penumbra's products are differentiated because of their computer assisted vacuum thrombectomy (CAVT) technology. CAVT utilizes algorithms to modulate the aspiration power depending on if a clot is detected, and to control a separate valve that injects saline to reduce friction between the clot and catheter. This maximizes clot removal while decreasing risk of blood loss. For U.S. thrombectomy, we see a market opportunity for over 1 million procedures a year across stroke and peripheral vascular, with a total addressable market (TAM) north of $8 billion. Of this TAM, Penumbra is only high single digits percentage penetrated in 2024. We are looking forward to this mechanism rolling out in the stroke setting (the Thunderbolt product which is in development). In addition, the company is seeing strong momentum in the venous setting already with their Flash product. We think this momentum could accelerate if the Storm-PE trial, which completed enrollment during the quarter, demonstrates superiority of Penumbra's CAVT plus anticoagulation versus anticoagulation alone (the current standard of care) in intermediate-high risk pulmonary embolism patients. The trial could change the treatment paradigm for pulmonary embolism." A close-up view of a technician wearing protective gloves while installing a mechanical thrombectomy system. Penumbra, Inc. (NYSE:PEN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held Penumbra, Inc. (NYSE:PEN) at the end of the first quarter, which was 35 in the previous quarter. In the second quarter of 2025, Penumbra, Inc. (NYSE:PEN) reported revenue of $339.5 million, marking year-over-year increase of 13.4% on a reported basis and 12.7% on a constant currency basis. While we acknowledge the potential of Penumbra, Inc. (NYSE:PEN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Penumbra, Inc. (NYSE:PEN) and shared the list of best mid-cap healthcare stocks to buy according to hedge funds. Baron Health Care Fund initiated a position in Penumbra, Inc. (NYSE:PEN) during Q1 2025. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Will Exact Sciences Corporation (EXAS) Continue to Penetrate the Market with Its Cologuard Test?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Exact Sciences Corporation (NASDAQ:EXAS). Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening and diagnostic test products. The one-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -12.29%, and its shares lost 19.18% of their value over the last 52 weeks. On July 30, 2025, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $46.80 per share, with a market capitalization of $8.828 billion. Baron Health Care Fund stated the following regarding Exact Sciences Corporation (NASDAQ:EXAS) in its second quarter 2025 investor letter: "We initiated a position in Exact Sciences Corporation (NASDAQ:EXAS), a molecular diagnostics company focused on the early detection of colorectal cancer. The company is best known for its non-invasive colorectal cancer stool tests, Cologuard and Cologuard Plus. 106 million adults in the U.S. are eligible for colorectal cancer screening, of which half are not up to date. Colonoscopies are the gold standard for colorectal cancer screening, but they are invasive and require significant preparation. In contrast, Cologuard is non-invasive and requires significantly less time commitment. Cologuard adoption is growing and the test now accounts for around 13% of colorectal cancer screening. We are increasingly hearing from doctors and patients that they are considering Cologuard ahead of colonoscopies. Shares underperformed in 2024 as adoption of Cologuard slowed, as investors anticipate competition from Guardant Health which launched a colorectal cancer blood test, and as investors feared a worst-case outcome from a Supreme Court case that potentially has implications for insurance coverage mandates for Cologuard. We think shares are well positioned to re-rate as each fear is dispelled: (1) we expect Exact Science's commercial restructuring to continue to drive volume growth reacceleration; (2) Guardant's blood test is less sensitive than Cologuard and we think blood tests will be relegated to patients who refuse more sensitive screening options; and (3) at the end of June, the Supreme Court issued its decision in the Braidwood case which preserved the insurance coverage mandate. We think Cologuard is a compelling option for colorectal cancer screening and Exact Sciences will continue to penetrate this market." A research team in a laboratory discussing the results of a lab screening test for biomarkers. Exact Sciences Corporation (NASDAQ:EXAS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Exact Sciences Corporation (NASDAQ:EXAS) at the end of the first quarter, which was 49 in the previous quarter. Exact Sciences Corporation's (NASDAQ:EXAS) first quarter revenue experienced 11% rise on reported and core basis exceeding the mid pint of guidance over $19 million. While we acknowledge the potential of Exact Sciences Corporation (NASDAQ:EXAS) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Exact Sciences Corporation (NASDAQ:EXAS) and shared the best mid cap pharma stocks to buy. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Police chief voices hope of agreement on dealing with legacy of NI's Troubles
Northern Ireland's chief constable has expressed hope for a new agreement on how to deal with the legacy of the region's troubled past. Jon Boutcher was speaking following a commemoration to remember three musicians from the Miami Showband who were killed in a loyalist ambush close to Newry 50 years ago. Mr Boutcher was among a crowd who visited a memorial on the Buskhill Road on Thursday afternoon to remember Fran O'Toole, Tony Geraghty and Brian McCoy. Those gathered included Michael Gallagher, whose son Aiden was killed in the 1998 Omagh bomb, and Eugene Reavey, whose brothers Anthony, John Martin and Brian were shot dead in an attack at their family home in Co Armagh in January 1976. Mr Boutcher told media: 'There are still so many uncertainties for so many people, and that's not right. 'Everybody knows my position on legacy, I think transparency and openness are critical. The report that I did on Operation Kenova reflects that, and I am very alive to and aware of national security issues. I have been involved with those all of my professional career, I know them better than anybody in policing, so you can do both. 'I think we may be close to coming to a position, and certainly I hope we are, where there will be a new agreement around what the future of legacy looks like, and I'm keen to hear the fruits of the recent talks between the two governments.' He added: 'We have now got to get legacy right. 'At the time that a lot of these cases occurred, half the community didn't trust police or security forces, which I understand. 'The volume of things that were happening, the murders, the attacks, meant that the security forces couldn't deal with them. There was then without doubt failures within a number of those investigations. We have now got to put that right.' Mr Boutcher said he had been invited to attend the commemoration by Miami Showband survivors Des Lee and Stephen Travers. 'I'd consider them to be people who have inspired me, helped me understand legacy here,' he said. 'I've spent a significant amount of time with both men and they have taught me a lot, and asked me if I would be here, and they are the example of what humility, courage and actually what this word reconciliation is all about. 'I'm here because it is the very least I could do, to be here.' Mr Lee paid tribute to Mr Boutcher as he spoke during the event as a special person he would like to thank. 'He is a gentleman who has helped me quite a lot in the past, he's now the leader of the PSNI and he is here with us today to commemorate the 50th anniversary,' he said.